Post

Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial

New RCT article published in Asian Pacific Journal of Tropical Medicine. Niaee, Namdar et al.

Concludes that Ivermectin as an adjunct reduces the rate of mortality, time of low O2 saturation, and duration of hospitalization in adult COVID-19 patients. The improvement of other clinical parameters shows that ivermectin, with a wide margin of safety, had a high therapeutic effect on COVID-19.

Download the article

View on Journal Website

Please Contribute

Let's Get Ivermectin Approved

Safe, cheap, beats Covid

Please support our campaign with a monthly or a single amount to help us keep pressure on authorities to approve the safe drug ivermectin that will help beat covid-19 and save lives around the world.

Bird Group/EBMC Squared is a not-for-profit Community Interest Company (CIC).

All funds received will be invested in our activities to promote public health and wellbeing.

Please contribute

Your monthly or single contribution will help us keep pressure on authorities to approve the safe drug ivermectin that will help beat covid-19 and save lives around the world.